Publication Name	World Journal of Gastroenterology
Manuscript ID	6979
Country	China

Received	2013-10-31 11:33
Peer-Review Started	2013-10-31 20:20
First Decision by Editorial Office Director
Return for Revision	2013-12-17 19:44
Revised	2014-01-16 13:31
Publication Fee Transferred
Second Decision by Editor	2014-04-09 09:20
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-04-09 11:01
Articles in Press	2014-05-23 09:25
Edit the Manuscript by Language Editor	2014-04-29 16:37
Typeset the Manuscript	2014-06-06 16:32
Publish the Manuscript Online	2014-07-03 15:30

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients
Manuscript Source	Invited Manuscript
All Author List	Gong-Ying Chen, Meng-Fei Zhu, Da-Liang Zheng, Yan-Ting Bao, Jie Wang, Xiang Zhou and Guo-Qiang Lou
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Zhejiang Province, China Y210435
Corresponding Author	Dr. Guo-Qiang Lou, Hospital Affiliated to Hangzhou Normal University, 126 Wenzhou Road, Hangzhou 310015, Zhejiang Province, China. louguoqiang2008@126.com
Key Words	Chronic hepatitis B; Hepatitis B surface antigen; Baseline; Virological response; Pegylated interferon-α2b
Core Tip	The response to antiviral therapy in chronic hepatitis B (CHB) patients varies significantly among individuals. This retrospective study of 55 patients evaluated the predictive effect of baseline hepatitis B surface antigen (HBsAg) on virological response in HBeAg-positive CHB patients treated with pegylated interferon (PEG-IFN)-α2b. The results suggest that baseline HBsAg level in combination with HBV DNA quantitative values may become an effective predictor for guiding optimal therapy with PEG-IFN-α2b against HBeAg-positive CHB.
Publish Date	2014-07-03 15:30
Citation	Chen GY, Zhu MF, Zheng DL, Bao YT, Wang J, Zhou X, Lou GQ. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B. World J Gastroenterol 2014; 20(25): 8195-8200
URL	http://www.wjgnet.com/1007-9327/full/v20/i25/8195.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i25.8195

Full Article (PDF)	WJG-20-8195.pdf
Full Article (Word)	WJG-20-8195.doc
Manuscript File	6979-Review.doc
Answering Reviewers	6979-Answering reviewers.pdf
Copyright License Agreement	6979-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6979-Language certificate.pdf
Peer-review Report	6979-Peer review(s).pdf
Scientific Editor Work List	6979-Scientific editor work list.doc